DanielWCoyneMD
Nephrology • Saint Louis, MOProfessor, Internal Medicine, Washington University School of Medicine
Dr. Coyne is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110Phone+1 314-362-7603Fax+1 314-747-5213
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Nephrology, 1987 - 1989
Emory University School of MedicineResidency, Internal Medicine, 1983 - 1986
Case Western Reserve University School of MedicineClass of 1983
Certifications & Licensure
MO State Medical License 1989 - 2025
OH State Medical License 1990 - 1994
GA State Medical License 1984 - 1989- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Nephrology
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Nephrology
Clinical Trials
- The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients Start of enrollment: 2006 Apr 01
- Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) Start of enrollment: 2009 Feb 01
Publications & Presentations
PubMed
- 20 citationsClinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling EraBorut Cizman, Helen T. Smith, Rodrigo Refoios Camejo, Linda N. Casillas, Harjeet Dhillon
Kidney Medicine. 2020-09-01 - 37 citationsManagement of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.Dennis L. Andress, Daniel W. Coyne, Kamyar Kalantar-Zadeh, Mark E. Molitch, Farhad Zangeneh
Endocrine Practice. 2008-01-01 - 144 citationsParicalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.Daniel W. Coyne, Muralidhar Acharya, Ping Qiu, Hanna E. Abboud, Daniel Batlle
American Journal of Kidney Diseases. 2006-02-01
Other
- The Value of Intravenous Iron: Beyond the Cave of SpeculationDaniel Coyne, MD, American Society of Nephrology
https://www.doximity.com/articles/b6612a40-619b-4786-9597-ad389c1683b1
UpToDate, Wolters Kluwer Health - 2012-10-24
Press Mentions
Akebia and GSK Will Grapple with Heightened Scrutiny of HIF PHIs After Roxadustat ConcernsAugust 24th, 2021- 1A? No Way. KDOQI Has Lost Its WayMay 14th, 2021
- Pooled Results of Roxadustat Phase 3 StudiesApril 15th, 2021
- Join now to see all
Grant Support
- Differential Effects Of Doxercalciferol (HECTORAL) And 19-Nor-1,25 DihydroxyNational Center For Research Resources2005
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
